Literature DB >> 6196112

Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: overview and pharmacology.

R M Allen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6196112     DOI: 10.1097/00002826-198300061-00009

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


× No keyword cloud information.
  6 in total

Review 1.  Emerging therapies in traumatic brain injury.

Authors:  Patrick M Kochanek; Travis C Jackson; Nikki Miller Ferguson; Shaun W Carlson; Dennis W Simon; Erik C Brockman; Jing Ji; Hülya Bayır; Samuel M Poloyac; Amy K Wagner; Anthony E Kline; Philip E Empey; Robert S B Clark; Edwin K Jackson; C Edward Dixon
Journal:  Semin Neurol       Date:  2015-02-25       Impact factor: 3.420

2.  Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations.

Authors:  M Brenner; A Haass; P Jacobi; K Schimrigk
Journal:  J Neurol       Date:  1989-03       Impact factor: 4.849

3.  Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome.

Authors:  J Kornhuber; M Weller
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 4.  Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis.

Authors:  James W Bales; Amy K Wagner; Anthony E Kline; C Edward Dixon
Journal:  Neurosci Biobehav Rev       Date:  2009-04-01       Impact factor: 8.989

Review 5.  NMDA antagonists for treating the non-motor symptoms in Parkinson's disease.

Authors:  Brigitte Vanle; William Olcott; Jaime Jimenez; Luma Bashmi; Itai Danovitch; Waguih William IsHak
Journal:  Transl Psychiatry       Date:  2018-06-15       Impact factor: 6.222

Review 6.  Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.

Authors:  Wojciech Danysz; Andrzej Dekundy; Astrid Scheschonka; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.